LILRB2 (MK-4830 Biosimilar) Recombinant Monoclonal Antibody

This recombinant monoclonal antibody is developed as a research-grade biosimilar to MK-4830, targeting LILRB2 (Leukocyte Immunoglobulin-Like Receptor B2), also known as ILT4 or CD85d. LILRB2 is an inhibitory immune checkpoint receptor expressed primarily on myeloid cells, including monocytes, macrophages, and dendritic cells. Upon binding to its ligands, including classical and non-classical MHC class I molecules, LILRB2 delivers immunosuppressive signals that dampen immune responses. This receptor plays a critical role in maintaining immune tolerance but is frequently exploited by tumors to create an immunosuppressive microenvironment, making it an important target in cancer immunotherapy research. LILRB2 overexpression has been associated with various malignancies, including acute myeloid leukemia and solid tumors.

MK-4830 is a clinical-stage therapeutic antibody designed to block LILRB2 signaling and restore anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating LILRB2-mediated immune regulation, studying myeloid cell function, and exploring combination immunotherapy strategies in preclinical models.